1. "Gregory Riely"
  2. "Naiyer Rizvi"
Formats
  1. Journal Article (17)
  2. Meeting Abstract (12)
  3. Research Letter (1)
Groups
  1. Department of Medicine (30)
  2. Solid Tumor Oncology Division (30)
  3. Thoracic Oncology (30)
  4. Radiology, Department of (15)
  5. Body Imaging Service (14)
  6. GSK Faculty (8)

More Groups

People
  1. Gregory Riely (30)
  2. Naiyer Rizvi (30)
  3. Mark Kris (29)
  4. Christopher Azzoli (20)
  5. Vincent Miller (19)
  6. Lee Krug (14)

More People

Years
  1. 2019 (1)
  2. 2013 (5)
  3. 2012 (5)
  4. 2011 (4)
  5. 2010 (3)
  6. 2009 (4)

More Years

Publications
  1. Journal of Clinical Oncology (11)
  2. Journal of Thoracic Oncology (9)
  3. Clinical Cancer Research (4)
  4. Cancer (2)
  5. Cancer Chemotherapy and Pharmacology (2)
  6. Lung Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (11)
  2. Elsevier Inc. (9)
  3. American Association for Cancer Research (4)
  4. Springer (2)
  5. Wiley Blackwell (2)
  6. Elsevier Ireland Ltd. (1)

More Publishers

Results (30)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials
    Meeting Abstract

    Drilon, A. E. D.; Wang, L.; Hasanovic, A.; Joubert, P.; Kris, M. G.; Riely, G. J.; Ladanyi, M.; Rizvi, N. A.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Ret fusion-positive advanced lung cancers: Response to first-line chemotherapy and survival in comparison to ROS1 and ALK fusion-positive and EGFR- and KRAS-mutant lung cancers
    Meeting Abstract

    Drilon, A.; Wang, L.; Joubert, P.; Snyder, A.; Cho, E. J.; Riely, G.; Kris, M.; Ladanyi, M.; Rizvi, N.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
    Journal Article

    Hellmann, M. D.; Chaft, J. E.; Rusch, V.; Ginsberg, M. S.; Finley, D. J.; Kris, M. G.; Price, K. A. R.; Azzoli, C. G.; Fury, M. G.; Riely, G. J.; more...
    Cancer Chemotherapy and Pharmacology (2013)

    Fulltext@MSK | Save
  • Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers
    Journal Article

    Chaft, J. E.; Rusch, V.; Ginsberg, M. S.; Paik, P. K.; Finley, D. J.; Kris, M. G.; Price, K. A. R.; Azzoli, C. G.; Fury, M. G.; Riely, G. J.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Journal Article

    Yu, H. A.; Sima, C. S.; Huang, J.; Solomon, S. B.; Rimner, A.; Paik, P.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Drilon, A. E. D.; Varghese, A. M.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; Kris, M. G.; Miller, V. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • 5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial
    Meeting Abstract

    Drilon, A. E. D. C.; Kyuichi, K.; Huberman, K. H.; Sima, C. S.; Fiore, J. J.; Yu, H. A.; Varghese, A. M.; Sumner, D. K.; Travis, W. D.; Heguy, A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Quantitating pathologic response to neoadjuvant chemotherapy in KRAS-mutated versus nonmutated lung cancers
    Meeting Abstract

    Chaft, J. E.; Paik, P. K.; Sima, C. S.; Kris, M. G.; Krug, L. M.; Azzoli, C. G.; Riely, G. J.; Pietanza, M. C.; Rusch, V. W.; Travis, W. D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer
    Journal Article

    Pietanza, M. C.; Gadgeel, S. M.; Dowlati, A.; Lynch, T. J.; Salgia, R.; Rowland, K. M. Jr; Wertheim, M. S.; Price, K. A.; Riely, G. J.; Azzoli, C. G.; more...
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save